# Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

> **NCT01682876** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 715 (actual)

## Conditions studied

- Meningococcal Disease
- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** MenACWY-CRM

## Key facts

- **NCT ID:** NCT01682876
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-07
- **Primary completion:** 2013-07-02
- **Final completion:** 2014-05-30
- **Target enrollment:** 715 (ACTUAL)
- **Last updated:** 2019-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682876, "Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01682876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*